ERBB2 and breast carcinoma: IL-12 therapy has demonstrated moderate efficacy in several tumor types, including HER2-positive breast cancer, melanoma, and renal cell carcinoma, but questions remain about the optimal dose in relation to the toxicity profile (2, 3).